528 material Form 8-K filings that 462 companies we cover made with the SEC in January 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Alignment Healthcare said it had about 209,900 health plan members as of January 1, 2025, up about 35% year over year, and expects 225,000 to 231,000 members by December 31, 2025. It reaffirmed its 2024 guidance and its confidence in about $40 million of adjusted EBITDA in 2025, with 2025 guidance to come on its fourth-quarter earnings call. The filing also says Dawn Maroney was promoted to President, effective immediately, to oversee day-to-day operations, while the filing provides no fourth-quarter or full-year 2024 results.
Health plan membership of about 209,900 as of January 1, 2025, up about 35% from January 1, 2024
Expects 225,000 to 231,000 members as of December 31, 2025, about 22% to 25% growth versus the midpoint of year-end 2024 membership guidance
Reaffirmed 2024 guidance: revenue of $2,665 million to $2,680 million and adjusted EBITDA of ($10) million to $5 million
Dawn Maroney promoted to President effective January 13, 2025; she reports to founder and CEO John Kao
Progyny said on January 13, 2025 that fourth-quarter 2024 revenue, net income and Adjusted EBITDA are now expected to be slightly above the ranges it gave in November. The company said member activity paced better than its guidance assumed, which had expected activity to be flat to down. The filing gives no specific dollar figures for the updated expectations.
Updated expectations cover the quarter and year ending December 31, 2024, and were issued January 13, 2025 in Exhibit 99.1.
Revenue, net income and Adjusted EBITDA for Q4 2024 are now expected to be slightly above the November guidance ranges.
CEO Pete Anevski will present at the JP Morgan Healthcare Conference on January 14, 2025 at 7:30 a.m. Pacific Time.
Alnylam said preliminary full-year 2024 global net product revenues were $1,646 million, up 33% from 2023, and fourth-quarter revenues were approximately $451 million. The company also guided to 2025 combined net product revenue of $2,050 million to $2,250 million and expects non-GAAP operating income profitability in 2025, which matters to shareholders because it sets the company's first public outlook for the year. The figures are unaudited and subject to adjustment before full results in February 2025.
Preliminary Q4 2024 global net product revenues were approximately $451 million; full-year 2024 was $1,646 million, up 33%.
2025 combined net product revenue guidance is $2,050 million to $2,250 million, or 31% growth at the midpoint.
Total TTR guidance is $1,600 million to $1,725 million; Total Rare guidance is $450 million to $525 million.
Full results are due in February 2025; the vutrisiran heart-disease PDUFA target action date is March 23, 2025.
Moderna disclosed preliminary, unaudited 2024 product sales of $3.0-3.1 billion and year-end cash of about $9.5 billion, ahead of its January 13, 2025 J.P. Morgan presentation. It also set a 2025 revenue range of $1.5-2.5 billion, mostly in the second half, and projected 2025 cash cost reductions of $1.0 billion and year-end 2025 cash of about $6.0 billion. The 2024 figures remain subject to the ongoing audit, and the filing gives no prior-year comparison for the new 2025 range.
Unaudited 2024 product sales of $3.0-3.1 billion, including $1.7 billion in the U.S.
Year-end 2024 cash, cash equivalents and investments of about $9.5 billion (unaudited).
2025 revenue projected at $1.5-2.5 billion, mostly in the second half; 2025 cash cost reductions of $1.0 billion, with a further $0.5 billion planned for 2026.
Expected year-end 2025 cash and investments of about $6.0 billion; full results due February 14, 2025.
US Foods reaffirmed its fiscal 2024 guidance, first given on its Nov. 7, 2024 third quarter earnings call, and did not change any of the ranges. The company also said CEO Dave Flitman and CFO Dirk Locascio will take part in a fireside chat at the 27th Annual ICR Conference on Jan. 14, 2025, which investors can hear by live webcast.
Net sales guidance reaffirmed at $37.7 billion to $38.0 billion for fiscal 2024
Adjusted EBITDA guidance reaffirmed at $1.72 billion to $1.74 billion
Adjusted diluted EPS guidance reaffirmed at $3.05 to $3.15
Fireside chat with Dave Flitman and Dirk Locascio on Jan. 14, 2025 at 9:30 a.m. EST
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.